Mode
Text Size
Log in / Sign up

Oncology

858 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CPAP therapy shows no significant reduction in cancer incidence among obstructive sleep apnea patients
Oncology Meta-analysis
CPAP therapy shows no significant reduction in cancer incidence among obstructive sleep apnea patients Does treating sleep apnea with CPAP lower your cancer risk? The answer isn't clear
A meta-analysis of three RCTs in OSA patients found no statistically significant difference in cancer incidence between CPAP and control gro…
Treating sleep apnea with CPAP does not appear to markedly reduce the risk of incident cancers, according to a new analysis of three large t…
Home test kits may boost cervical cancer screening, but evidence details are lacking
Oncology
Home test kits may boost cervical cancer screening, but evidence details are lacking Can a home test kit help more women get screened for cervical cancer?
A review of article headlines suggests home test kits may increase cervical cancer screening, but no study details, methodology, or results …
Home test kits appear to boost cervical cancer screening rates by offering a private, convenient way for women to take control of their heal…
California's COVID-19 stay-at-home order associated with affected cervical cancer screening rates
Oncology
California's COVID-19 stay-at-home order associated with affected cervical cancer screening rates Did pandemic lockdowns cause women to miss cervical cancer screenings?
An observational report from a large Southern California health system found that cervical cancer screening rates for women aged 21-65 were …
California's pandemic lockdowns likely caused women to miss cervical cancer screenings, delaying early detection of pre-cancerous changes.
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Oncology Sys. Review
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes.
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
Meta-analysis finds 32% higher breast cancer mortality hazard for Indigenous women despite lower incidence
Oncology Meta-analysis
Meta-analysis finds 32% higher breast cancer mortality hazard for Indigenous women despite lower incidence Indigenous women face higher breast cancer mortality despite lower incidence rates
A systematic review and meta-analysis of 61 studies across seven countries found Indigenous women had lower breast cancer incidence but a 32…
Indigenous women have lower breast cancer rates but face a 32% higher risk of dying from the disease compared to non-Indigenous women.
Observational report examines breast cancer survival rates in US males
Oncology
Observational report examines breast cancer survival rates in US males Study examines survival rates for men with breast cancer in the United States
An observational report examined breast cancer survival in males in the United States.
A new report describes the survival rate of males diagnosed with breast cancer in the United States.
Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain Metastases
Oncology Cohort
Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain Metastases Can a gentler radiation schedule help control melanoma that has spread to the brain?
A retrospective single-center study of 26 patients with melanoma brain metastases found hypofractionated radiotherapy achieved 96% disease c…
A gentle radiation schedule controlled bleeding brain tumors in 100% of cases while shrinking most melanoma growths without severe side effe…
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor
Oncology
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor What happens when a rare cancer returns? One young woman's story offers a clue
A case report describes a 23-year-old woman with neurofibromatosis type 1 and Malignant Triton Tumor.
A 23-year-old woman with a rare chest tumor found disease stabilization after surgery failed, using a mix of chemotherapy, targeted therapy,…
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Oncology
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC).
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer
Oncology FDA Approval
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer FDA approves a new targeted cancer drug called Krazati for lung and colorectal cancers
The FDA has approved Krazati as a single agent for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least…
FDA approves Krazati, a new targeted drug for lung and colorectal cancers with a specific genetic change after other treatments fail.
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
Oncology FDA Approval
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
Oncology FDA Approval
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy The FDA approved a new treatment for a type of blood cancer called multiple myeloma
The FDA has approved Elrexfio, a bispecific BCMA-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myelom…
A new FDA-approved treatment helps shrink multiple myeloma in patients who have already tried at least four other therapies.